Drugs / Iron sucrose
Iron sucrose
also known as
Venofer · FeS · Iron saccharate · FERIV · ferric sucrose · iron sucrose DIN 02502917 · Iron Sucrose Injection · iron sucrose injection - Venofer · +6 more
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | VENOFER | — | 2003-06-02 – 2012-09-21 | fda.gov ↗ |
| Approved | US (FDA) | VENOFER | — | 2000-11-06 | fda.gov ↗ |
Trials 62
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03630029 | Sep → Nov 2018 | acute kidney injury | Renibus Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT01265108 | Nov 2010 → Jan 2015 | — | University of Oxford | Completed | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT01978535 | Dec 2014 → Sep 2017 | postural orthostatic tachycardia syndrome | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00125996 | Jul 2004 → Feb 2006 | iron deficiency anemia, symptomatic heart failure | National Heart and Lung Institute | Unknown | Missed primary |
| Phase 212 trials · 1 met primary | ||||||
| Phase 2 | NCT05800600 | Mar 2023 → Feb 2027 expected | anemia | Fox Chase Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04564833 | Aug 2021 → Nov 2022 | acute kidney injury | Renibus Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT04855266 | Apr 2021 → May 2023 | iron deficiency anemia, postural orthostatic tachycardia syndrome | Mayo Clinic | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03528564 | Jul 2019 → May 2021 | anemia due to chronic disorder, arthropathy, iron deficiency anemia | Unity Health Toronto | Terminated | No outcome recorded |
| Phase 2 | NCT02977611 | Jan → May 2017 | iron deficiency anemia | The Guthrie Clinic | Withdrawn | No outcome recorded |
| Phase 2 | NCT02047552 | Jan 2015 → Dec 2017 | anemia, disorder of iron metabolism and transport | Denver Health and Hospital Authority | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01438372 | Nov 2011 → Feb 2012 | inflammatory bowel disease, iron deficiency anemia | Wayne State University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01309659 | May 2011 → Feb 2013 | anemia | Duke University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00721188 | Jan 2006 → Jul 2008 | anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00895232 | Nov 2003 → Aug 2005 | restless legs syndrome | American Regent, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00239616 | Jun 2002 → Sep 2003 | anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00960921 | — | pulmonary hypertension | University of Oxford | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00386126 | Aug 2006 → ? | anemia, heart failure | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 311 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT06248749 | Feb 2024 → Dec 2028 expected | anemia | University of Saskatchewan | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04464850 | Jul 2020 → Jan 2021 | iron deficiency anemia | Chiang Mai University | Unknown | No outcome recorded |
| Phase 3 | NCT03009578 | Feb 2017 → Apr 2018 | anemia | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT01857011 | Apr 2014 → Apr 2016 | iron deficiency anemia | Federal University of São Paulo | Completed | Missed primary |
| Phase 3 | NCT01435200 | Jun 2011 → Oct 2012 | female reproductive organ cancer | Chulalongkorn University | Completed | Met primary |
| Phase 3 | NCT00384657 | Jan 2008 → Dec 2017 | anemia, chronic kidney disease, heart failure | Anemia Working Group Romania | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT00202345 | Aug 2004 → Feb 2007 | anemia, kidney failure | Melbourne Health | Completed | No outcome recorded |
| Phase 3 | NCT00145652 | Dec 2003 → Dec 2005 | B-cell chronic lymphocytic leukemia, anemia, plasma cell myeloma | Sundsvall Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00236977 | Aug 2003 → Oct 2004 | anemia | American Regent, Inc. | Completed | Met primary |
| Phase 3 | NCT00236938 | Jul 2002 → Sep 2004 | anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00236964 | Feb 2001 → May 2002 | anemia | American Regent, Inc. | Completed | Mixed |
| Phase 421 trials · 2 missed | ||||||
| Phase 4 | NCT06703411 | May 2023 → Oct 2024 | disorder of iron metabolism and transport, systolic heart failure | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05489952 | Sep 2022 → Feb 2025 | osteoporosis | He Qifei | Unknown | No outcome recorded |
| Phase 4 | NCT05734716 | Feb 2021 → Aug 2022 | acute mountain sickness | University of Oregon | Completed | No outcome recorded |
| Phase 4 | NCT02787824 | May → Oct 2016 | anemia due to chronic disorder | Papageorgiou General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02544828 | Nov 2015 → Jul 2016 | osteoarthritis | Konkuk University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02390921 | Feb → Oct 2015 | iron metabolism disease | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02060851 | Feb → Jun 2014 | nutritional deficiency disease | Kunshan First People's Hospital Affiliated to Jiangsu University | Completed | No outcome recorded |
| Phase 4 | NCT01084122 | May 2010 → Dec 2012 | — | Hospital Clinic of Barcelona | Unknown | No outcome recorded |
| Phase 4 | NCT01067547 | Mar 2010 → Dec 2013 | inflammatory bowel disease, iron deficiency anemia | Richard Fedorak | Completed | No outcome recorded |
| Phase 4 | NCT00746551 | Sep 2008 → Mar 2010 | anemia, pregnancy disorder | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00830037 | Aug 2008 → Nov 2014 | chronic kidney disease, iron deficiency anemia | Indiana University | Terminated | Missed primary |
| Phase 4 | NCT01078818 | May 2007 → May 2009 | anemia | Fundación Canaria Rafael Clavijo para la Investigación Biomédica | Completed | Missed primary |
| Phase 4 | NCT00354692 | Jun → Nov 2006 | chronic kidney disease, iron deficiency anemia | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02392910 | Mar 2006 → Feb 2012 | chronic kidney disease, heart failure, iron deficiency anemia | Hospital Aleman | Completed | No outcome recorded |
| Phase 4 | NCT00308490 | Sep 2005 → Jan 2007 | anemia due to chronic disorder | Papageorgiou General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00239642 | Jul 2005 → Jan 2009 | anemia, chronic kidney disease | American Regent, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00204256 | Mar 2004 → Mar 2005 | chronic renal failure syndrome | University Hospital Muenster | Unknown | No outcome recorded |
| Phase 4 | NCT03317210 | Sep 2002 → Jul 2006 | anemia | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT06690450 | Aug 2001 → Jan 2002 | — | American Regent, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00199277 | — | colorectal neoplasm, iron deficiency anemia | J. Uriach and Company | Unknown | No outcome recorded |
| Phase 4 | NCT01151592 | — | iron deficiency anemia | American Regent, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase not applicable12 trials | ||||||
| — | NCT06994065 | Apr → Sep 2025 | iron deficiency anemia | Sindh Institute of Urology and Transplantation | Completed | No outcome recorded |
| — | NCT07115121 | Feb → Jul 2025 | anemia | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06012760 | Jan 2025 → Jan 2028 expected | iron deficiency anemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05353348 | Mar 2023 → Apr 2025 overdue | iron deficiency anemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT06596161 | Feb 2023 → Feb 2024 | myalgic encephalomeyelitis/chronic fatigue syndrome | Central Park Medical College | Completed | No outcome recorded |
| — | NCT04491916 | Apr 2020 → Dec 2022 | anemia, end stage renal failure | Kaohsiung Medical University Chung-Ho Memorial Hospital | Unknown | No outcome recorded |
| — | NCT03610230 | Feb 2019 → Mar 2021 | iron deficiency anemia | The University of Hong Kong | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT03516500 | May 2018 → Jan 2021 | lung neoplasm | Ruijin Hospital | Completed | No outcome recorded |
| — | NCT01443624 | Oct 2011 → Jan 2013 | critical illness polyneuropathy | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00952302 | Oct → Nov 2008 | chronic mountain sickness, pulmonary hypertension | University of Oxford | Completed | Mixed |
| — | NCT01012063 | Aug 2008 → Oct 2009 | anemia | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT00560976 | Dec 2005 → Dec 2014 | end stage renal failure | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05151679 | — | iron deficiency anemia | Assiut University | Available | No outcome recorded |
| Comparator or background therapy38 trials | ||||||
| Phase 1 | NCT02009943 Comparator | Feb → Aug 2017 | anemia, disorder of iron metabolism and transport | Denver Health and Hospital Authority | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT00534144 Comparator | Sep 2007 → Nov 2008 | chronic renal failure syndrome, iron deficiency anemia | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT07657091 Comparator | Jan → Jun 2027 expected | iron deficiency anemia | Kharadar General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06487299 Comparator | Jul 2024 → Jan 2026 overdue | iron deficiency anemia | The Second Hospital of Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01052779 Comparator | Mar 2010 → Jul 2011 | anemia, disorder of iron metabolism and transport, kidney disorder | AMAG Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01290315 Comparator | Aug 2009 → Mar 2013 | iron deficiency anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00318812 Comparator | May 2007 → Dec 2011 | chronic kidney disease, iron deficiency anemia | Ottawa Hospital Research Institute | Completed | Missed primary |
| Phase 2/3 | NCT00557817 Comparator | Mar 2004 → Aug 2008 | hematopoietic and lymphoid cell neoplasm | University of Liege | Completed | No outcome recorded |
| Phase 3 | NCT06366698 Comparator | Nov 2023 → Dec 2025 | iron deficiency anemia | Arrowhead Regional Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT05251493 Comparator | Jun 2022 → Dec 2026 expected | iron deficiency anemia | Saskatchewan Health Authority - Regina Area | Recruiting | No outcome recorded |
| Phase 3 | NCT03893045 Comparator | Sep 2019 → Jul 2026 overdue | iron deficiency anemia | AMAG Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03619850 Comparator | Aug 2018 → Aug 2026 overdue | chronic kidney disease, iron deficiency anemia | AMAG Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03591406 Comparator | Jul 2017 → Feb 2019 | iron deficiency anemia | Vifor (International) Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02940860 Comparator | Nov 2016 → May 2018 | chronic kidney disease, iron deficiency anemia | Pharmacosmos A/S | Completed | Met primary |
| Phase 3 | NCT02940886 Comparator | Nov 2016 → Mar 2018 | iron deficiency anemia | Pharmacosmos A/S | Completed | Met primary |
| Phase 3 | NCT02130063 Comparator | May 2014 → Aug 2015 | iron deficiency anemia | Pharmacosmos A/S | Completed | No outcome recorded |
| Phase 3 | NCT02390102 Comparator | Jun 2012 → Jun 2015 | anemia, aortic valve stenosis | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Completed | No outcome recorded |
| Phase 3 | NCT01222884 Comparator | Jun 2011 → Oct 2013 | end stage renal failure | Pharmacosmos A/S | Completed | No outcome recorded |
| Phase 3 | NCT01114204 Comparator | Aug 2010 → Nov 2011 | iron deficiency anemia | AMAG Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00981045 Comparator | Aug 2009 → Jul 2011 | impaired renal function disease, iron deficiency anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00810030 Comparator | Oct 2008 → Dec 2009 | Crohn disease, disorder of iron metabolism and transport, iron deficiency anemia, ulcerative colitis | Vifor Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00704353 Comparator | Jun 2008 → Jul 2009 | anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00236951 Comparator | Feb 2003 → Oct 2005 | anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT06911034 Comparator | Feb → Jul 2024 | iron deficiency anemia, pregnancy disorder | CMH Multan Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT06061393 Comparator | Nov 2023 → Sep 2027 expected | iron deficiency anemia | Western Galilee Hospital-Nahariya | Recruiting | No outcome recorded |
| Phase 4 | NCT05921968 Comparator | Jul 2023 → Jan 2024 | iron deficiency anemia | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT05691257 Background | Feb → Aug 2023 | anemia, chronic kidney disease, heart failure | China-Japan Friendship Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06556134 Comparator | Jul 2021 → Jul 2023 | anemia due to chronic disorder | Centre Hospitalier Hassan II - Fès | Completed | No outcome recorded |
| Phase 4 | NCT04225728 Comparator | Dec 2017 → Jun 2018 | disorder of iron metabolism and transport, heart failure | CN NGANOU-GNINDJIO, MD, MSc | Completed | No outcome recorded |
| Phase 4 | NCT02707757 Comparator | Jul 2015 → Dec 2016 | anemia | Imperial College Healthcare NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT03658876 Comparator | Jun 2015 → Dec 2016 | anemia, chronic renal failure syndrome | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT02198495 Comparator | Sep 2014 → May 2019 | anemia due to chronic disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01227616 Comparator | Aug 2013 → Feb 2016 | chronic kidney disease, iron deficiency anemia | AMAG Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 4 | NCT00593619 Comparator | Jan 2008 → Dec 2009 | iron deficiency anemia | London Health Sciences Centre | Suspended | No outcome recorded |
| Phase 4 | NCT00660933 Comparator | Sep 2005 → Sep 2007 | anemia, puerperal disorder | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| — | NCT01888003 Comparator | Apr 2013 → Jan 2015 | iron deficiency anemia | University of Alabama at Birmingham | Terminated | No outcome recorded |
| — | NCT01180894 Comparator | Jun 2011 → Sep 2013 | anemia | Denver Health and Hospital Authority | Completed | No outcome recorded |
| — | NCT01349699 Comparator | Feb → May 2010 | anemia, autoinflammatory syndrome | Radboud University Medical Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-08-11 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Regulatory Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. viatris.com ↗
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients (2 years of age and older) with chronic kidney disease (CKD). |
| 2025-08-11 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Announces FDA Approval for Iron Sucrose Injection, USP amphastar.com ↗ |
| 2019-01-22 | CSL Behring | Results Vifor Pharma Press Release Updated on Analysis of Venofer in High Dosage Study csl.com ↗
The re-analysis of the data revealed a statistically significant improvement in the treatment effects of a higher dose of Venofer® (i.v. iron sucrose) compared with a lower dose. |
| 2018-10-29 | CSL Behring | Results Pivotal trial confirms long-term safety and efficacy of IV iron dosing strategy csl.com ↗
The trial met its primary endpoint of noninferiority as assessed by a composite of death and cardiovascular events, demonstrating that a liberal, proactive intravenous (IV) iron dosing regimen did not expose patients to an increased level of harm |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-11 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. viatris.com ↗ |
| 2025-08-11 | Amphastar Pharmaceuticals, Inc. | Amphastar Announces FDA Approval for Iron Sucrose Injection, USP amphastar.com ↗ |
| 2021-01-20 | Pharmascience Inc. | Pharmascience inc. lance pms-IRON SUCROSE pour le traitement de l’anémie ferriprive pharmascience.com ↗ |
| 2019-01-22 | CSL Behring | Vifor Pharma Press Release Updated on Analysis of Venofer in High Dosage Study csl.com ↗ |
| 2018-10-29 | CSL Behring | Pivotal trial confirms long-term safety and efficacy of IV iron dosing strategy csl.com ↗ |
| 2008-07-09 | Daiichi Sankyo | Luitpold Pharmaceuticals/American Regent and Fresenius Medical Care sign agreements for exclusive sublicense of Venofer(R)in U.S. daiichisankyo.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 101 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iron sucrose | “RBT-1 is a combination drug of stannic protoporfin (SnPP) and iron sucrose (FeS) that elicits a preconditioning response through activation of antioxidant, anti-inflammatory,...” PMID 38586479 ↗ Jan 202488“We developed an intraoperative novel method for distinguishing intersegmental planes of the lung via transbronchial injection of iron sucrose (ClinicalTrials.gov number, NCT03516500).” PMID 37096093 ↗ Jan 2023 “Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)” NCT05691257 ↗ “12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.” NCT03630029 ↗ “IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose.” NCT00830037 ↗ “The study group received 200mg of intravenous iron sucrose immediately after each chemotherapy infusion.” PMID 24099839 ↗ Oct 2013 “Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session.” NCT04464850 ↗ “Iron Sucrose, Iron Gluconate or Iron Isomaltoside (Treatment group A) versus No Iron Infusion treatment” NCT06248749 ↗ “5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg.” NCT01978535 ↗ “5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted” NCT04855266 ↗ “500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland)” NCT00746551 ↗ |
| Known as | FERIV | “Iron sucrose FERIV® (20 mg/ml).” NCT01084122 ↗ |
| Known as | ferric sucrose | “intravenous iron (ferric sucrose product Venofer® 2%, 5mL/ampoule)” NCT00384657 ↗ |
| Known as | FeS | “RBT-1 is a combination drug of stannic protoporfin (SnPP) and iron sucrose (FeS) that elicits a preconditioning response through activation of antioxidant, anti-inflammatory,...” PMID 38586479 ↗ Jan 20241“FeS (Iron Sucrose) SnPP (Stannous Protoporpyhrin” NCT03630029 ↗ |
| Known as | Iron saccharate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00557817 ↗ |
| Known as | iron sucrose DIN 02502917 | “iron sucrose DIN 02502917” NCT05251493 ↗ |
| Known as | Iron Sucrose Injection | “Venofer (Iron Sucrose Injection)” NCT00721188 ↗ |
| Known as | iron sucrose injection - Venofer | “iron sucrose injection - Venofer” NCT00895232 ↗ |
| Known as | iron sucrose injection, USP | “iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks” NCT00534144 ↗ |
| Known as | iron(III)-hydroxide sucrose complex | “Group I (n = 54): intravenous iron(III)-hydroxide sucrose complex, three doses of 100 mg/24 h during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in...” PMID 22940889 ↗ Aug 2012 |
| Known as | sacrofer | “Women will receive iron sucrose (sacrofer ampules 100 mg/5ml)” NCT03009578 ↗ |
| Known as | Venofer | “A Randomized Open-label Trial Cross-over Trial of Iron Isomaltoside 1000 (Monofer®) Compared With Iron Sucrose (Venofer®) in Peritoneal Dialysis Patients” NCT03610230 ↗20“500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland)” NCT00746551 ↗ “intravenous iron (ferric sucrose product Venofer® 2%, 5mL/ampoule)” NCT00384657 ↗ “Ferrous Sulfate, Venofer, Ferrlecit, Infed, Dexferrum” NCT00704353 ↗ “IV Iron Saccharate (Venofer)100 mg” NCT00560976 ↗ “Venofer (intravenous iron sucrose)” NCT00125996 ↗ “Venofer (iron sucrose injection)” NCT00239642 ↗ “Drug: Iron sucrose (Venofer)” NCT05734716 ↗ “iron sucrose (Venofer®)” NCT02130063 ↗ “Iron sucrose = Venofer” NCT01265108 ↗ “Iron Sucrose (Venofer)” NCT00981045 ↗ |
| Known as | Venofer (iron sucrose) | “Venofer (iron sucrose)” NCT00960921 ↗ |
| Known as | Venofer (TM) | “5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg.” NCT01978535 ↗ |
| Known as | Venofer Luitpold Pharmaceuticals, NDC # 00517-2340-10 | “Venofer Luitpold Pharmaceuticals, NDC # 00517-2340-10” NCT01438372 ↗ |
| Route | Intravenous | “intravenous (IV) iron supplementation” NCT00125996 ↗ |